Use of extended half life factor VIII products in children with severe hemophilia A on prophylaxis: A single centre experience

被引：0
|
作者：
Komitopoulou, A. [1 ]
Pergantou, H. [1 ]
Mazarakis, M. [1 ]
Kapsimali, Z. [1 ]
Karelioti, E. [1 ]
Dettoraki, A. [1 ]
Platokouki, H. [1 ]
机构：
[1] Aghia Sophia Childrens Hosp, Haemostasis Unit, Haemophilia Ctr, Athens, Greece
来源：
HAEMOPHILIA | 2018年 / 24卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P050
引用
收藏
页码：54 / 54
页数：1
相关论文
共 50 条
  • [21] A single centre retrospective study of low dose prophylaxis with extended half-life factor IX for severe haemophilia B
    Rampotas, Alexandros
    Desborough, Michael J. R.
    Raza-Burton, Sayma
    Taylor, Stephanie
    Wilkinson, Alice
    Hall, Georgina W.
    Shapiro, Susan
    Curry, Nicola
    HAEMOPHILIA, 2020, 26 (02) : 278 - 281
  • [22] CLINICAL APPLICATION OF EXTENDED HALF-LIFE PEGYLATED FACTOR VIII IN CHILDREN WITH SEVERE HAEMOPHILIA A
    Dettoraki, A.
    Michalopoulou, A.
    Mazarakis, M.
    Saslis, S.
    Stamati, I.
    Kapsimali, Z.
    Pergantou, H.
    HAEMOPHILIA, 2022, 28 : 44 - 45
  • [23] Limited sampling strategies for accurate determination of extended half-life factor VIII pharmacokinetics in severe hemophilia A patients
    Goggans, Margaret H.
    Barker, Patricia J.
    Jacobs, Timothy W.
    Neufeld, Ellis J.
    Reiss, Ulrike M.
    Panetta, John C.
    McEneny-King, Alanna
    HAEMOPHILIA, 2018, 24 : 89 - 89
  • [24] ECONOMIC EVALUATION OF RECOMBINANT EXTENDED HALF-LIFE FACTOR VIII PROPHYLAXIS FOR PEOPLE WITH HEMOPHILIA A - A SYSTEMATIC REVIEW (COSTIVE PROJECT)
    Araujo, M. S.
    Camelo, R. M.
    Cedro, V. Q. M.
    Dos Santos, B. R. A.
    Azevedo, P. S.
    Pereira, A. C.
    HAEMOPHILIA, 2023, 29 : 53 - 53
  • [25] A multi-centre study to investigate the association of terminal half-life of factor VIII with quality of life in severe hemophilia A patients
    Chen, Yeu-Chin
    Cheng, Shin-Nan
    Yu, Ming-Sun
    Chen, Shu-Huey
    Fang, Yi-Ping
    Hou, Jen-Yin
    Chang, Hung
    Chen, Chih-Cheng
    Hsiao, Chih-Cheng
    Wang, Hsiang-Wei
    Lin, Jia-Hong
    Yu, Lennex Hsueh-Lin
    HAEMOPHILIA, 2020, 26 : 8 - 8
  • [26] PHARMACOKINETIC DRUG EVALUATION OF STANDARD HALF-LIFE AND EXTENDED HALF-LIFE FACTOR VIII IN PATIENTS WITH HEMOPHILIA A
    Lopez-Jaime, F-J
    Perez-Raya, M.
    Doblas-Marquez, A.
    Martin-Tellez, S.
    Mena-Santano, A-M
    Munoz-Lopez, F-D
    HAEMOPHILIA, 2021, 27 : 107 - 107
  • [27] Individualization of prophylaxis with recombinant factor VIII in severe or moderate hemophilia A
    Megias Vericat, J. E.
    Marques, R.
    Haya, S.
    Cid, A. R.
    Querol, F.
    Monte, E.
    Garcias Dasi, M.
    Caunedo, P.
    Bosch, P.
    Curats, R.
    Poveda, J. L.
    Bonanad, S.
    HAEMOPHILIA, 2018, 24 : 92 - 93
  • [28] Factor VIII Products and Inhibitor Development in Severe Hemophilia A
    Gouw, Samantha C.
    van der Bom, Johanna G.
    Ljung, Rolf
    Escuriola, Carmen
    Cid, Ana R.
    Claeyssens-Donadel, Segolene
    van Geet, Christel
    Kenet, Gili
    Makipernaa, Anne
    Molinari, Angelo Claudio
    Muntean, Wolfgang
    Kobelt, Rainer
    Rivard, George
    Santagostino, Elena
    Thomas, Angela
    van den Berg, H. Marijke
    NEW ENGLAND JOURNAL OF MEDICINE, 2013, 368 (03): : 231 - 239
  • [29] Factor VIII Products and Inhibitors in Severe Hemophilia A REPLY
    van den Berg, H. Marijke
    Gouw, Samantha C.
    van der Bom, Johanna G.
    NEW ENGLAND JOURNAL OF MEDICINE, 2013, 368 (15): : 1457 - 1457
  • [30] Single centre experience comparing Factor VIII half-life to von Willebrand factor levels and blood group in a cohort of severe haemophilia A patients
    Stanley, Jenna
    Pigden, Collette
    Day, Tina
    HAEMOPHILIA, 2018, 24 : 131 - 131
12345